blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2943578

EP2943578 - DNAZYME FOR SILENCING THE EXPRESSION OF EGFR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.02.2020
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  08.03.2019
FormerGrant of patent is intended
Status updated on  06.11.2018
FormerExamination is in progress
Status updated on  16.03.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
National Taiwan University
No. 1, Sec.4, Roosevelt Road
Taipei 10617 / TW
For all designated states
Academia Sinica
128, Sec. 2
Academia Sinica Road
Nan-Kang
Taipei 115 / TW
[2019/15]
Former [2015/47]For all designated states
National Taiwan University
No. 1, Sec.4, Roosevelt Road
Taipei 10617 / TW
For all designated states
Academia Sinica
128 Academia Road
Section 2
Nankang, Taipei, 115 / TW
Inventor(s)01 / YANG, Pan-chyr
1 Jen-Ai Road
Section 1
Taipei 10051 / TW
02 / LAI, Wei-Yun
128 Academia Road
Section 2
Nankang
Taipei 115 / TW
03 / PECK, Konan
"-"
"deceased" / TW
04 / CHANG, Cheng-Ju
128, ACADEMIA ROAD, Section 2
Nankang
Taipei 115, Taiwan / TW
05 / CHEN, Chi-Yuan
128, ACADEMIA ROAD, Section 2
Nankang
Taipei 115, Taiwan / TW
06 / YANG, Shuenn-Chen
128, ACADEMIA ROAD, Section 2
Nankang
Taipei 115, Taiwan / TW
 [2019/15]
Former [2017/46]01 / YANG, Pan-chyr
1 Jen-Ai Road
Section 1
Taipei 10051 / TW
02 / LAI, Wei-Yun
128 Academia Road
Section 2
Nankang
Taipei 115 / TW
03 / PECK, Konan
"-"
"deceased" / TW
04 / CHANG, Cheng-Ju
128, ACADEMIA ROAD, Section 2
Nankang
Taipei 115, Taiwan / CN
05 / CHEN, Chi-Yuan
128, ACADEMIA ROAD, Section 2
Nankang
Taipei 115, Taiwan / CN
06 / YANG, Shuenn-Chen
128, ACADEMIA ROAD, Section 2
Nankang
Taipei 115, Taiwan / CN
Former [2015/47]01 / YANG, Pan-chyr
1 Jen-Ai Road
Section 1
Taipei 10051 / TW
02 / LAI, Wei-Yun
128 Academia Road
Section 2
Nankang
Taipei 115 / TW
03 / PECK, Konan
128 Academia Road, Section 2, Nankang
Taipei 115 Taiwan Province of China / TW
Representative(s)Lavoix
Bayerstraße 83
80335 München / DE
[N/P]
Former [2019/15]Lavoix
Bayerstrasse 83
80335 München / DE
Former [2015/47]Tischner, Oliver, et al
Lavoix Munich
Bayerstrasse 83
80335 München / DE
Application number, filing date14737655.214.01.2014
[2015/47]
WO2014US11496
Priority number, dateUS201361752117P14.01.2013         Original published format: US 201361752117 P
[2015/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014110577
Date:17.07.2014
Language:EN
[2014/29]
Type: A1 Application with search report 
No.:EP2943578
Date:18.11.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 17.07.2014 takes the place of the publication of the European patent application.
[2015/47]
Type: B1 Patent specification 
No.:EP2943578
Date:10.04.2019
Language:EN
[2019/15]
Search report(s)International search report - published on:US17.07.2014
(Supplementary) European search report - dispatched on:EP23.12.2016
ClassificationIPC:A61K31/713, C12N15/113
[2018/46]
CPC:
C12N15/1138 (EP,US); A61K31/517 (EP,US); A61K31/713 (EP,US);
A61P35/00 (EP); A61P43/00 (EP); C07K14/485 (EP,US);
C12N2310/127 (EP,US); C12N2310/315 (EP,US); C12N2310/33 (EP,US);
C12N2310/3515 (EP,US); C12N2320/31 (EP,US); C12N2320/34 (EP,US) (-)
Former IPC [2015/47]C12P19/34, C12N9/00, A61K48/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/47]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:DNAZYM ZUM AUSSCHALTEN DER EXPRESSION VON EGFR[2015/47]
English:DNAZYME FOR SILENCING THE EXPRESSION OF EGFR[2015/47]
French:ADN À ACTIVITÉ CATALYTIQUE SERVANT À SUPPRIMER L'EXPRESSION DE L'EGFR[2015/47]
Entry into regional phase07.08.2015National basic fee paid 
07.08.2015Search fee paid 
07.08.2015Designation fee(s) paid 
07.08.2015Examination fee paid 
Examination procedure07.08.2015Examination requested  [2015/47]
03.07.2017Amendment by applicant (claims and/or description)
15.03.2018Despatch of a communication from the examining division (Time limit: M04)
09.07.2018Reply to a communication from the examining division
07.11.2018Communication of intention to grant the patent
27.02.2019Fee for grant paid
27.02.2019Fee for publishing/printing paid
27.02.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.03.2018
Opposition(s)13.01.2020No opposition filed within time limit [2020/12]
Fees paidRenewal fee
11.01.2016Renewal fee patent year 03
11.01.2017Renewal fee patent year 04
15.01.2018Renewal fee patent year 05
09.01.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.01.2014
AL10.04.2019
AT10.04.2019
CY10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
MC10.04.2019
MK10.04.2019
MT10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SI10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
[2022/32]
Former [2022/27]HU14.01.2014
AL10.04.2019
AT10.04.2019
CY10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
MC10.04.2019
MT10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SI10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/39]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
MC10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SI10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/26]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SI10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/17]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SK10.04.2019
SM10.04.2019
TR10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/14]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SK10.04.2019
SM10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/12]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
IT10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SK10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/11]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
EE10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
SK10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/10]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RO10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/09]AL10.04.2019
AT10.04.2019
CZ10.04.2019
DK10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/04]AL10.04.2019
AT10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
IS10.08.2019
PT10.09.2019
Former [2020/03]AL10.04.2019
AT10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
PT10.09.2019
Former [2019/52]AL10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
PL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
PT10.09.2019
Former [2019/51]AL10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
RS10.04.2019
SE10.04.2019
BG10.07.2019
NO10.07.2019
GR11.07.2019
PT10.09.2019
Former [2019/50]AL10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
LV10.04.2019
NL10.04.2019
RS10.04.2019
SE10.04.2019
NO10.07.2019
GR11.07.2019
PT10.09.2019
Former [2019/49]AL10.04.2019
ES10.04.2019
FI10.04.2019
HR10.04.2019
LT10.04.2019
NL10.04.2019
SE10.04.2019
NO10.07.2019
PT10.09.2019
Former [2019/48]ES10.04.2019
FI10.04.2019
LT10.04.2019
NL10.04.2019
SE10.04.2019
NO10.07.2019
PT10.09.2019
Former [2019/47]ES10.04.2019
FI10.04.2019
LT10.04.2019
NL10.04.2019
NO10.07.2019
Former [2019/44]NL10.04.2019
Documents cited:Search[XI]WO2012043633  (NAT CT NEUROLOGY & PSYCHIATRY [JP], et al) [X] 1,2,15,16 * figure 22; example 4 * [I] 1-4,7-23;
 [P]EP2623600  (NAT CT NEUROLOGY & PSYCHIATRY [JP]) [P] * page 32, paragraph 172 - page 33, paragraph 177; figure 22; example 4; table 8 *;
 [XI]  - CHEN GANG ET AL, "Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, (20121222), vol. 431, no. 3, doi:10.1016/J.BBRC.2012.12.070, ISSN 0006-291X, pages 623 - 629, XP028980106 [X] 1,2,15,16 * the whole document * [I] 1,2,7-15,17-23

DOI:   http://dx.doi.org/10.1016/j.bbrc.2012.12.070
 [I]  - GANG CHEN ET AL, "Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab", BMC MEDICINE, BIOMED CENTRAL LTD., LONDON, GB, (20120321), vol. 10, no. 1, doi:10.1186/1741-7015-10-28, ISSN 1741-7015, page 28, XP021123822 [I] 1,2,7-15,17-23 * the whole document *

DOI:   http://dx.doi.org/10.1186/1741-7015-10-28
 [T]  - WEI-YUN LAI ET AL, "Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme", MOLECULAR THERAPY-NUCLEIC ACIDS, (20140304), vol. 3, no. 3, doi:10.1038/mtna.2014.3, page e150, XP055286687

DOI:   http://dx.doi.org/10.1038/mtna.2014.3
 [A]  - ZHANG SHUANG ET AL, "Suppression of Epidermal Growth Factor Receptor (EGFR) Expression by Small Hairpin RNA Inhibits the Growth of Human Nonsmall Cell Lung Cancers Bearing Wild-type and Mutant EGFR", CANCER INVESTIGATION,, (20110101), vol. 29, no. 10, ISSN 0735-7907, pages 701 - 708, XP008180787 [A] 1,2,7-23
 [A]  - BEALE G ET AL, "GENE SILENCING NUCLEIC ACIDS DESIGNED BY SCANNING ARRAYS: ANTI-EGFR ACTIVITY OF SIRNA, RIBOZYME AND DNA ENZYMES TARGETING A SINGLE HYBRIDIZATION-ACCESSIBLE REGION USING THE SAME DELIVERY SYSTEM", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, (20030801), vol. 11, no. 7, doi:10.1080/1061186042000207039, ISSN 1061-186X, pages 449 - 456, XP009034373 [A] 1,2,7-23

DOI:   http://dx.doi.org/10.1080/1061186042000207039
International search[Y]US2011275072  (SESHAGIRI SOMASEKAR [US]);
 [Y]US2007048754  (FREEMAN DANIEL J [US], et al);
 [A]US2007020621  (BOUKHAROV ANDREY A [US], et al);
 [A]US2004031072  (LA ROSA THOMAS J [US], et al);
 [A]EP1767632  (SIRNA THERAPEUTICS INC [US], et al);
 [Y]  - CASSELL, A ET AL., "Investigational EGFR-Targeted Therapies In HNSCC.", EXPERT OPINION ON INVESTIGATIONAL DRUGS., (20100601), vol. 19, no. 6, doi:10.1517/13543781003769844, pages 709 - 722, XP055266140

DOI:   http://dx.doi.org/10.1517/13543781003769844
 [Y]  - YU , SH ET AL., "Specific Repression Of Mutant K-RAS By 10-23 DNAzyme: Sensitizing Cancer Cell To Anti-Cancer Therapies .", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., (20090109), vol. 378, no. 2, doi:10.1016/J.BBRC.2008.11.027, pages 230 - 234, XP025745435

DOI:   http://dx.doi.org/10.1016/j.bbrc.2008.11.027
 [Y]  - SHARMA , SV ET AL., "Epidermal Growth Gactor Receptor Mutations In Lung Cancer.", NATURE REVIEWS, (20070301), vol. 7, doi:10.1038/NRC2088, pages 169 - 181, XP002556732

DOI:   http://dx.doi.org/10.1038/nrc2088
 [Y]  - GLEAVE, M ET AL., "Progression To Androgen Independence Is Delayed By Adjuvant Treatment With Antisense Bcl-2 Oligodeoxynucleotides After Castration In The LNCaP Prostate Tumor Model.", CLINICAL CANCER RESEARCH, (19991001), vol. 8, pages 2891 - 2898, XP055266292
 [A]  - MAUCELI, E ET AL., "Culex Quinquefasciatus Calmodulin-Binding Transcription Activator,mRNA.", (20070326), pages 1 - 3, URL: http://http://http://www.ncbi.nim.nih.gov/nucleotide/170035313?report=genbank&log$=nuclalign&blaSuank=38&R.ID=NNXXFI:tCK01R, (20140425), XP055270582
ExaminationWO2004038019
    - KIM JI EUN ET AL, "Site-specific cleavage of mutantABLmRNA by DNAzyme is facilitated by peptide nucleic acid binding to RNA substrate", FEBS LETTERS, (20120923), vol. 586, no. 21, doi:10.1016/J.FEBSLET.2012.09.013, ISSN 0014-5793, pages 3865 - 3869, XP028953171

DOI:   http://dx.doi.org/10.1016/j.febslet.2012.09.013
    - Amr Abdelgany ET AL, "Selective DNAzyme-mediated cleavage of AChR mutant transcripts by targeting the mutation site or through mismatches in the binding arm", Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research, England, (20050101), pages 32 - 37, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737196/pdf/jrgs-01-032.pdf, XP055428068
    - Tong-Hong Wang ET AL, "The Use of 10-23 DNAzyme to Selectively Destroy the Allele of mRNA with a Unique Purine-Pyrimidine Dinucleotide", OLIGONUCLEOTIDES., US, (20080901), vol. 18, no. 3, doi:10.1089/oli.2008.0138, ISSN 1545-4576, pages 295 - 300, XP055428081

DOI:   http://dx.doi.org/10.1089/oli.2008.0138
by applicantUS2012225870
    - Journal of Drug Targeting, (20030800), vol. 11, no. 7, pages 449 - 456
    - Mol Cancer Ther, (20080000), vol. 7, no. 2, pages 243 - 51
    - SCHUBERT, S.; GUL, D.C., GRUNERT; H.P.; ZEICHHARDT, H.; ERDMANN, V.A.; KURRECK, J., "RNA cleaving '10-23' DNAzymes with enhanced stability and activity", Nucleic Acids Res, (20030000), vol. 31, doi:doi:10.1093/nar/gkg791, pages 5982 - 5992, XP002272988

DOI:   http://dx.doi.org/10.1093/nar/gkg791
    - DASS, C.R.; CHOONG, P.F.; KHACHIGIAN, L.M., "DNAzyme technology and cancer therapy: cleave and let die", Mol Cancer Ther, (20080000), vol. 7, doi:doi:10.1158/1535-7163.MCT-07-0510, pages 243 - 251, XP055174842

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-07-0510
    - BREAKER, R. R.; JOYCE, G., Chemistry and Biology, (19950000), vol. 2, no. 6, page 55
    - SANTORO; S. W. & JOYCE, G. F. Proc. Natl, Acad. Sci. USA, (19970000), vol. 94, page 4262
    - Nucleic Acids Res, vol. 36, pages 4768 - 4777
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.